Bioporto A/S
CSE:BIOPOR

Watchlist Manager
Bioporto A/S Logo
Bioporto A/S
CSE:BIOPOR
Watchlist
Price: 1.466 DKK 2.23%
Market Cap: 629.9m DKK

Bioporto A/S
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bioporto A/S
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Bioporto A/S
CSE:BIOPOR
Revenue
kr34.9m
CAGR 3-Years
12%
CAGR 5-Years
4%
CAGR 10-Years
7%
Genmab A/S
CSE:GMAB
Revenue
kr21.5B
CAGR 3-Years
37%
CAGR 5-Years
32%
CAGR 10-Years
38%
Zealand Pharma A/S
CSE:ZEAL
Revenue
kr62.7m
CAGR 3-Years
-17%
CAGR 5-Years
9%
CAGR 10-Years
-9%
Ascendis Pharma A/S
NASDAQ:ASND
Revenue
€363.6m
CAGR 3-Years
260%
CAGR 5-Years
94%
CAGR 10-Years
39%
B
Bavarian Nordic A/S
CSE:BAVA
Revenue
kr6.1B
CAGR 3-Years
57%
CAGR 5-Years
61%
CAGR 10-Years
20%
Saniona AB
STO:SANION
Revenue
kr26.7m
CAGR 3-Years
28%
CAGR 5-Years
40%
CAGR 10-Years
N/A

Bioporto A/S
Glance View

Market Cap
629.9m DKK
Industry
Biotechnology

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

BIOPOR Intrinsic Value
1.299 DKK
Overvaluation 11%
Intrinsic Value
Price

See Also

What is Bioporto A/S's Revenue?
Revenue
34.9m DKK

Based on the financial report for Sep 30, 2024, Bioporto A/S's Revenue amounts to 34.9m DKK.

What is Bioporto A/S's Revenue growth rate?
Revenue CAGR 10Y
7%

Over the last year, the Revenue growth was 5%. The average annual Revenue growth rates for Bioporto A/S have been 12% over the past three years , 4% over the past five years , and 7% over the past ten years .

Back to Top